Detalles de la búsqueda
1.
Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.
Diabetes Obes Metab
; 25(5): 1292-1300, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36655340
2.
Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
Diabetes Obes Metab
; 24(9): 1861-1868, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35589616
3.
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
Cardiovasc Diabetol
; 20(1): 194, 2021 09 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34563178
4.
Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
Diabetes Obes Metab
; 23(1): 106-115, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32945083
5.
Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study.
Diabetes Obes Metab
; 23(2): 508-519, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33140575
6.
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11.
Diabetes Obes Metab
; 23(10): 2242-2250, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34189841
7.
Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
Diabetes Obes Metab
; 21(4): 920-929, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30520248
8.
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
Diabetes Obes Metab
; 21(6): 1299-1304, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30714309
9.
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
Diabetes Obes Metab
; 19(7): 953-961, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28181725
10.
Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: physician knowledge, patient adherence.
J Am Pharm Assoc (2003)
; 54(2): 144-53, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24632930
11.
Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States.
J Manag Care Spec Pharm
; 30(2): 153-162, 2024 Feb 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38308628
12.
Seasonal patterns of abdominal pain consultations among adults and children.
J Pediatr Gastroenterol Nutr
; 56(3): 290-6, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23059641
13.
Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States.
Diabetes Ther
; 14(12): 2045-2055, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37770706
14.
Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Clin Gastroenterol Hepatol
; 10(3): 247-53, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22155561
15.
Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States.
Curr Med Res Opin
; 38(11): 1785-1795, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35758147
16.
Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.
Clin Ther
; 44(6): 873-887, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35618571
17.
Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.
Diabetes Ther
; 13(11-12): 1921-1932, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36131064
18.
Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.
Clin Ther
; 44(4): 537-554, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35264311
19.
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Am J Gastroenterol
; 106(3): 421-31, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21224838
20.
Development and psychometric evaluation of 2 age-stratified versions of the Pediatric GERD Symptom and Quality of Life Questionnaire.
J Pediatr Gastroenterol Nutr
; 52(5): 514-22, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21464757